Please use this identifier to cite or link to this item:
Title: FFA4/GPR120: Pharmacology and Therapeutic Opportunities.
Authors: Milligan, G
Alvarez-Curto, E
Hudson, BD
Prihandoko, R
Tobin, AB
First Published: 19-Jul-2017
Publisher: Elsevier (Cell Press) for Trends
Citation: Trends in Pharmacological Sciences, 2017, 38 (9), pp. 809-821
Abstract: Free Fatty Acid receptor 4 (FFA4), also known as GPR120, is a G-protein-coupled receptor (GPCR) responsive to long-chain fatty acids that is attracting considerable attention as a potential novel therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Although no clinical studies have yet been initiated to assess efficacy in this indication, a significant number of primary publications and patents have highlighted the ability of agonists with potency at FFA4 to improve glucose disposition and enhance insulin sensitivity in animal models. However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from cancer to lung function. Here, we discuss and contextualise the basis for these ideas and the results to support these conclusions.
DOI Link: 10.1016/
eISSN: 1873-3735
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © the authors, 2017. This is an open-access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Description: Resources
Appears in Collections:Published Articles, Dept. of Molecular and Cell Biology

Files in This Item:
File Description SizeFormat 
1-s2.0-S016561471730127X-main.pdfPublished (publisher PDF)2.11 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.